Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 15/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30965934 | 0.89 | CHRM3 (0.61) | TRPM8CHRM3 | |
| SCHEMBL25142600 | 0.88 | CHRM3 (0.58) | TRPM8HDAC3HDAC1HDAC8NCOR2 | |
| SCHEMBL1567179 | 0.88 | CHRM3 (0.58) | TRPM8HDAC3HDAC1HDAC8NCOR2 | |
| SCHEMBL3073178 | 0.87 | TRPM8 (0.67) | TRPM8HDAC3HDAC1HDAC8NCOR2 | |
| SCHEMBL29782631 | 0.86 | TRPM8 (0.54) | TRPM8CHRM3 | |
| SCHEMBL3185939 | 0.85 | TRPM8 (0.74) | TRPM8HDAC3HDAC1HDAC8NCOR2 | |
| SCHEMBL3185948 | 0.85 | TRPM8 (0.74) | TRPM8HDAC3HDAC1HDAC8NCOR2 | |
| SCHEMBL3059945 | 0.85 | TRPM8 (0.77) | TRPM8HDAC3HDAC1HDAC8NCOR2 | |
| SCHEMBL3059948 | 0.85 | TRPM8 (0.77) | TRPM8HDAC3HDAC1HDAC8NCOR2 | |
| SCHEMBL3052751 | 0.84 | TRPM8 (0.64) | TRPM8HDAC3HDAC1HDAC8NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476297-B2 | TRP-M8 receptor ligands and their use in treatments | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476297-B2 | TRP-M8 receptor ligands and their use in treatments | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009073203-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPM8, TRPV2 | TRPM8 2/4885HDAC3 1936/4885HDAC1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.